Matthew John Frigault, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 60 | 2024 | 1468 | 6.890 |
Why?
|
Neurotoxicity Syndromes | 11 | 2024 | 301 | 3.000 |
Why?
|
Receptors, Antigen, T-Cell | 15 | 2024 | 2549 | 2.050 |
Why?
|
Antigens, CD19 | 17 | 2024 | 424 | 1.980 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 13 | 2024 | 1405 | 1.900 |
Why?
|
Hematologic Neoplasms | 9 | 2024 | 1895 | 1.600 |
Why?
|
Central Nervous System Neoplasms | 5 | 2024 | 915 | 1.540 |
Why?
|
Lymphoma | 6 | 2024 | 1898 | 1.220 |
Why?
|
T-Lymphocytes | 30 | 2024 | 10203 | 1.140 |
Why?
|
Lymphoma, B-Cell | 4 | 2020 | 938 | 1.080 |
Why?
|
Hematopoietic Stem Cell Transplantation | 13 | 2024 | 5666 | 0.870 |
Why?
|
Multiple Myeloma | 9 | 2024 | 5145 | 0.710 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 299 | 0.700 |
Why?
|
Antigens, Neoplasm | 7 | 2024 | 1985 | 0.680 |
Why?
|
Lymphoma, Mantle-Cell | 3 | 2023 | 237 | 0.500 |
Why?
|
B-Cell Maturation Antigen | 5 | 2024 | 149 | 0.410 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2022 | 1549 | 0.410 |
Why?
|
Lymphohistiocytosis, Hemophagocytic | 2 | 2024 | 269 | 0.340 |
Why?
|
Transplantation, Autologous | 3 | 2024 | 2112 | 0.310 |
Why?
|
Humans | 95 | 2024 | 761208 | 0.310 |
Why?
|
Hematologic Diseases | 2 | 2023 | 496 | 0.290 |
Why?
|
Lentivirus | 3 | 2022 | 508 | 0.280 |
Why?
|
B-Lymphocytes | 1 | 2020 | 4744 | 0.270 |
Why?
|
Leukocytes, Mononuclear | 2 | 2022 | 1838 | 0.270 |
Why?
|
United States Food and Drug Administration | 3 | 2024 | 1662 | 0.250 |
Why?
|
Graft vs Host Disease | 3 | 2024 | 3025 | 0.250 |
Why?
|
Lymphoma, Non-Hodgkin | 3 | 2021 | 1372 | 0.240 |
Why?
|
Antigens, CD7 | 1 | 2024 | 29 | 0.240 |
Why?
|
Neoplasms | 8 | 2024 | 22140 | 0.230 |
Why?
|
Acute Kidney Injury | 3 | 2022 | 1923 | 0.230 |
Why?
|
Hodgkin Disease | 2 | 2021 | 1379 | 0.210 |
Why?
|
Genetic Engineering | 3 | 2022 | 930 | 0.210 |
Why?
|
Cytokines | 4 | 2022 | 7386 | 0.210 |
Why?
|
Aged | 22 | 2024 | 169288 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3093 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3215 | 0.200 |
Why?
|
Agammaglobulinemia | 1 | 2023 | 172 | 0.200 |
Why?
|
Glioblastoma | 3 | 2024 | 3482 | 0.190 |
Why?
|
Remission Induction | 2 | 2024 | 2392 | 0.190 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2024 | 494 | 0.180 |
Why?
|
Adult | 26 | 2024 | 221119 | 0.180 |
Why?
|
Blast Crisis | 1 | 2020 | 102 | 0.170 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 629 | 0.170 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2019 | 40 | 0.170 |
Why?
|
Retrospective Studies | 19 | 2024 | 80674 | 0.170 |
Why?
|
Philadelphia Chromosome | 1 | 2020 | 117 | 0.170 |
Why?
|
Anemia, Aplastic | 1 | 2021 | 230 | 0.170 |
Why?
|
Neoplasm Proteins | 2 | 2022 | 3594 | 0.160 |
Why?
|
Receptors, Interleukin-6 | 1 | 2020 | 224 | 0.160 |
Why?
|
Middle Aged | 20 | 2024 | 220853 | 0.160 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2020 | 109 | 0.160 |
Why?
|
Male | 25 | 2024 | 360693 | 0.150 |
Why?
|
Female | 26 | 2024 | 392544 | 0.150 |
Why?
|
Xenograft Model Antitumor Assays | 5 | 2019 | 3592 | 0.150 |
Why?
|
Biological Products | 3 | 2022 | 915 | 0.150 |
Why?
|
Lymphoma, Follicular | 1 | 2022 | 457 | 0.150 |
Why?
|
Treatment Outcome | 12 | 2024 | 64681 | 0.150 |
Why?
|
Flow Cytometry | 3 | 2024 | 5871 | 0.140 |
Why?
|
Transduction, Genetic | 1 | 2020 | 900 | 0.140 |
Why?
|
Mice, Inbred NOD | 3 | 2019 | 1822 | 0.140 |
Why?
|
Antigen-Presenting Cells | 1 | 2020 | 965 | 0.140 |
Why?
|
Carcinoma, Lobular | 1 | 2021 | 480 | 0.140 |
Why?
|
Antibodies, Bispecific | 1 | 2019 | 196 | 0.140 |
Why?
|
Immunomodulation | 2 | 2021 | 548 | 0.130 |
Why?
|
Mice, SCID | 3 | 2019 | 2621 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2024 | 1052 | 0.130 |
Why?
|
Lymphoma, T-Cell | 1 | 2018 | 303 | 0.130 |
Why?
|
Bone Marrow Transplantation | 2 | 2020 | 2692 | 0.130 |
Why?
|
Respiratory Tract Infections | 1 | 2023 | 1009 | 0.130 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2020 | 686 | 0.120 |
Why?
|
Cytokine-Induced Killer Cells | 1 | 2015 | 6 | 0.120 |
Why?
|
Neoplasm Recurrence, Local | 6 | 2024 | 9278 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 2 | 2020 | 1605 | 0.120 |
Why?
|
Lymphocytes | 1 | 2023 | 2603 | 0.120 |
Why?
|
Recurrence | 2 | 2024 | 8457 | 0.120 |
Why?
|
Salvage Therapy | 1 | 2021 | 1264 | 0.120 |
Why?
|
Antigens, CD | 1 | 2024 | 4009 | 0.110 |
Why?
|
Drug Approval | 1 | 2020 | 812 | 0.110 |
Why?
|
Bacteremia | 1 | 2020 | 978 | 0.110 |
Why?
|
Tumor Escape | 1 | 2016 | 371 | 0.110 |
Why?
|
Respiratory Insufficiency | 1 | 2021 | 1232 | 0.100 |
Why?
|
Recombinant Fusion Proteins | 3 | 2017 | 3726 | 0.100 |
Why?
|
Central Nervous System | 3 | 2023 | 1333 | 0.100 |
Why?
|
Lymphocyte Activation | 3 | 2019 | 5478 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2020 | 1589 | 0.090 |
Why?
|
Chemokines | 1 | 2015 | 956 | 0.090 |
Why?
|
Bone Marrow | 1 | 2020 | 2911 | 0.090 |
Why?
|
Syndecan-4 | 1 | 2009 | 45 | 0.090 |
Why?
|
Young Adult | 9 | 2024 | 59221 | 0.090 |
Why?
|
Immunophenotyping | 1 | 2015 | 1867 | 0.080 |
Why?
|
Anti-Retroviral Agents | 1 | 2019 | 1784 | 0.080 |
Why?
|
Th1 Cells | 1 | 2014 | 1042 | 0.080 |
Why?
|
Terminal Care | 1 | 2021 | 1760 | 0.080 |
Why?
|
Aged, 80 and over | 3 | 2024 | 58952 | 0.080 |
Why?
|
T-Cell Antigen Receptor Specificity | 2 | 2019 | 84 | 0.080 |
Why?
|
Immunotherapy | 2 | 2020 | 4642 | 0.070 |
Why?
|
Troponin | 2 | 2023 | 504 | 0.070 |
Why?
|
Interleukin-2 | 1 | 2015 | 1891 | 0.070 |
Why?
|
Follow-Up Studies | 3 | 2024 | 39126 | 0.070 |
Why?
|
Th17 Cells | 1 | 2014 | 794 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2019 | 2813 | 0.070 |
Why?
|
Animals | 12 | 2024 | 168079 | 0.070 |
Why?
|
Age Factors | 1 | 2024 | 18384 | 0.070 |
Why?
|
Disease Progression | 2 | 2020 | 13511 | 0.070 |
Why?
|
C-Reactive Protein | 3 | 2023 | 3821 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2022 | 3609 | 0.070 |
Why?
|
Cyclophosphamide | 2 | 2023 | 2219 | 0.060 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2021 | 5300 | 0.060 |
Why?
|
Neoplasm Staging | 1 | 2020 | 11119 | 0.060 |
Why?
|
Genetic Vectors | 1 | 2015 | 3388 | 0.060 |
Why?
|
Quality of Life | 2 | 2024 | 13367 | 0.060 |
Why?
|
Mechanotransduction, Cellular | 1 | 2009 | 528 | 0.060 |
Why?
|
HIV-1 | 1 | 2022 | 6851 | 0.060 |
Why?
|
Prognosis | 5 | 2024 | 29687 | 0.060 |
Why?
|
Disease Management | 3 | 2020 | 2507 | 0.060 |
Why?
|
HIV Infections | 2 | 2022 | 17347 | 0.060 |
Why?
|
Cardiovascular Diseases | 2 | 2020 | 15520 | 0.060 |
Why?
|
United States | 5 | 2024 | 72339 | 0.050 |
Why?
|
Registries | 1 | 2019 | 8247 | 0.050 |
Why?
|
Survival Rate | 3 | 2024 | 12728 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2019 | 10422 | 0.050 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2022 | 5321 | 0.050 |
Why?
|
Tumor Microenvironment | 1 | 2016 | 3873 | 0.050 |
Why?
|
Mutation | 3 | 2022 | 30002 | 0.050 |
Why?
|
Bone Marrow Examination | 1 | 2021 | 155 | 0.050 |
Why?
|
Sickle Cell Trait | 1 | 2021 | 85 | 0.050 |
Why?
|
Histiocytes | 1 | 2021 | 98 | 0.050 |
Why?
|
Epistaxis | 1 | 2021 | 112 | 0.050 |
Why?
|
Purpura | 1 | 2021 | 117 | 0.050 |
Why?
|
Oropharynx | 1 | 2021 | 137 | 0.050 |
Why?
|
Transgenes | 1 | 2024 | 1008 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13632 | 0.040 |
Why?
|
Adolescent | 4 | 2024 | 88298 | 0.040 |
Why?
|
Child | 3 | 2023 | 80152 | 0.040 |
Why?
|
Intubation | 1 | 2020 | 139 | 0.040 |
Why?
|
Pandemics | 1 | 2020 | 8663 | 0.040 |
Why?
|
Pyrazoles | 2 | 2021 | 2010 | 0.040 |
Why?
|
Mice | 7 | 2024 | 81326 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2020 | 125 | 0.040 |
Why?
|
Pharyngitis | 1 | 2021 | 220 | 0.040 |
Why?
|
Lymphocyte Depletion | 1 | 2022 | 602 | 0.040 |
Why?
|
Certification | 1 | 2023 | 418 | 0.040 |
Why?
|
Macrophage Activation | 1 | 2022 | 552 | 0.040 |
Why?
|
Heart Failure | 1 | 2023 | 11701 | 0.040 |
Why?
|
Water-Electrolyte Balance | 1 | 2020 | 325 | 0.040 |
Why?
|
Pyrimidines | 2 | 2021 | 3027 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 9025 | 0.040 |
Why?
|
Ciprofloxacin | 1 | 2020 | 312 | 0.040 |
Why?
|
Ovarian Neoplasms | 1 | 2015 | 4872 | 0.040 |
Why?
|
Tissue and Organ Harvesting | 1 | 2020 | 373 | 0.040 |
Why?
|
Ferritins | 1 | 2020 | 596 | 0.040 |
Why?
|
Laboratories | 1 | 2021 | 462 | 0.040 |
Why?
|
Electroencephalography | 2 | 2023 | 6242 | 0.040 |
Why?
|
Neutropenia | 1 | 2022 | 885 | 0.040 |
Why?
|
Lung Neoplasms | 1 | 2022 | 13385 | 0.040 |
Why?
|
Immunity, Humoral | 1 | 2021 | 598 | 0.030 |
Why?
|
Cell Line, Tumor | 3 | 2019 | 16952 | 0.030 |
Why?
|
Death | 1 | 2021 | 677 | 0.030 |
Why?
|
Perception | 1 | 2022 | 1198 | 0.030 |
Why?
|
Nitriles | 1 | 2021 | 971 | 0.030 |
Why?
|
Cytotoxicity, Immunologic | 1 | 2019 | 1351 | 0.030 |
Why?
|
Antibiotic Prophylaxis | 1 | 2020 | 637 | 0.030 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2023 | 2024 | 0.030 |
Why?
|
Signal Transduction | 2 | 2015 | 23416 | 0.030 |
Why?
|
Interleukin Receptor Common gamma Subunit | 1 | 2014 | 87 | 0.030 |
Why?
|
Treatment Failure | 1 | 2020 | 2643 | 0.030 |
Why?
|
Guidelines as Topic | 1 | 2020 | 1385 | 0.030 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1225 | 0.030 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2020 | 2509 | 0.030 |
Why?
|
Radiopharmaceuticals | 1 | 2023 | 2683 | 0.030 |
Why?
|
Breast Neoplasms | 1 | 2021 | 20982 | 0.030 |
Why?
|
Incidence | 2 | 2023 | 21365 | 0.030 |
Why?
|
Depression | 2 | 2024 | 8132 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2022 | 3155 | 0.030 |
Why?
|
Survivors | 1 | 2024 | 2369 | 0.030 |
Why?
|
Disease Susceptibility | 1 | 2020 | 1791 | 0.030 |
Why?
|
Acute Disease | 1 | 2024 | 7226 | 0.030 |
Why?
|
Protein Binding | 2 | 2019 | 9297 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2022 | 2046 | 0.030 |
Why?
|
Interleukin-6 | 1 | 2023 | 3210 | 0.030 |
Why?
|
Risk Factors | 1 | 2020 | 74239 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 3134 | 0.030 |
Why?
|
Stem Cell Transplantation | 1 | 2021 | 1600 | 0.030 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2023 | 2897 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2020 | 8003 | 0.030 |
Why?
|
Transplantation Conditioning | 1 | 2019 | 1591 | 0.030 |
Why?
|
K562 Cells | 1 | 2014 | 640 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2021 | 2455 | 0.030 |
Why?
|
Transplantation, Homologous | 1 | 2021 | 4822 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6124 | 0.020 |
Why?
|
Caregivers | 1 | 2024 | 2244 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2019 | 1895 | 0.020 |
Why?
|
Survival Analysis | 1 | 2023 | 10088 | 0.020 |
Why?
|
Pilot Projects | 1 | 2024 | 8642 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2024 | 4574 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2020 | 5250 | 0.020 |
Why?
|
Communication | 1 | 2024 | 3872 | 0.020 |
Why?
|
Interleukins | 1 | 2014 | 782 | 0.020 |
Why?
|
Bioengineering | 1 | 2009 | 99 | 0.020 |
Why?
|
T-Lymphocyte Subsets | 1 | 2017 | 1803 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2021 | 3048 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2009 | 818 | 0.020 |
Why?
|
Mass Screening | 1 | 2024 | 5426 | 0.020 |
Why?
|
Interleukin-17 | 1 | 2014 | 913 | 0.020 |
Why?
|
Patient Selection | 1 | 2020 | 4246 | 0.020 |
Why?
|
NIH 3T3 Cells | 1 | 2009 | 667 | 0.020 |
Why?
|
Anxiety | 1 | 2022 | 4569 | 0.020 |
Why?
|
Boston | 1 | 2020 | 9327 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2024 | 14610 | 0.020 |
Why?
|
Patient Acceptance of Health Care | 1 | 2021 | 3200 | 0.020 |
Why?
|
Kidney | 1 | 2022 | 7033 | 0.020 |
Why?
|
Surface Properties | 1 | 2009 | 1162 | 0.020 |
Why?
|
Carcinoma, Hepatocellular | 1 | 2019 | 2293 | 0.020 |
Why?
|
Double-Blind Method | 1 | 2020 | 12341 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 12976 | 0.020 |
Why?
|
Fibronectins | 1 | 2009 | 724 | 0.020 |
Why?
|
Cognition | 1 | 2023 | 6988 | 0.020 |
Why?
|
Stroke Volume | 1 | 2019 | 5521 | 0.020 |
Why?
|
Integrins | 1 | 2009 | 835 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2021 | 10218 | 0.010 |
Why?
|
Apoptosis | 1 | 2019 | 9477 | 0.010 |
Why?
|
Cell Adhesion | 1 | 2009 | 3091 | 0.010 |
Why?
|
Liver Neoplasms | 1 | 2019 | 4309 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2021 | 5333 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2021 | 20119 | 0.010 |
Why?
|
MAP Kinase Signaling System | 1 | 2009 | 1480 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2019 | 11509 | 0.010 |
Why?
|
Antibodies | 1 | 2009 | 2415 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2020 | 7407 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26071 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18220 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 11733 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2014 | 14392 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 18926 | 0.010 |
Why?
|
Child, Preschool | 1 | 2020 | 42224 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41496 | 0.010 |
Why?
|
Models, Biological | 1 | 2009 | 9457 | 0.010 |
Why?
|